Cell-free therapy: a neuroregenerative approach to sensory neuropathy?

Submitted by Ana Maria Fiscina Sampaio ([email protected]) on 2019-08-07T13:42:17Z No. of bitstreams: 1 Villareal, C.F. Cell-free therapy... 2019.pdf: 202951 bytes, checksum: 68bde7428021452f98a33aac1002aa7c (MD5)Approved for entry into archive by Ana Maria Fiscina Sampaio ([email protected]) on 2019-08-07T14:06:40Z (GMT) No. of bitstreams: 1 Villareal, C.F. Cell-free therapy... 2019.pdf: 202951 bytes, checksum: 68bde7428021452f98a33aac1002aa7c (MD5)Made available in DSpace on 2019-08-07T14:06:40Z (GMT). No. of bitstreams: 1 Villareal, C.F. Cell-free therapy... 2019.pdf: 202951 bytes, checksum: 68bde7428021452f98a33aac1002aa7c (MD5) Previous issue date: 2019Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Farmácia. Salvador, BA, Brasil / Instituto Nacional de Ciência e Tecnologia. Instituto de Investigação em Imunologia. São Paulo, SP, Brasil

Opioid-based micro and nanoparticulate formulations: alternative approach on pain management

Submitted by Ana Maria Fiscina Sampaio ([email protected]) on 2017-05-31T19:35:35Z No. of bitstreams: 1 São Pedro A Opioid-based micro....pdf: 1317810 bytes, checksum: 2be9c3779af52bfd7d7a1620e85edb8b (MD5)Approved for entry into archive by Ana Maria Fiscina Sampaio ([email protected]) on 2017-05-31T19:49:48Z (GMT) No. of bitstreams: 1 São Pedro A Opioid-based micro....pdf: 1317810 bytes, checksum: 2be9c3779af52bfd7d7a1620e85edb8b (MD5)Made available in DSpace on 2017-05-31T19:49:48Z (GMT). No. of bitstreams: 1 São Pedro A Opioid-based micro....pdf: 1317810 bytes, checksum: 2be9c3779af52bfd7d7a1620e85edb8b (MD5) Previous issue date: 2016Universidade Federal da Bahia. Escola Politécnica. Programa de Pós Graduação em Engenharia Industrial. Salvador, BA, BrasilUniversidade Federal da Bahia. Faculdade de Farmácia. Programa de Pós-Graduação em Farmácia. Salvador, BA, BrasilUniversidade Federal da Bahia. Faculdade de Farmácia. Programa de Pós-Graduação em Farmácia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Laboratório de Imunofarmacologia e Engenharia Tecidual. Salvador, BA, BrasilUniversidade Federal da Bahia. Escola Politécnica. Programa de Pós Graduação em Engenharia Industrial. Salvador, BA, BrasilUniversidade Federal da Bahia. Escola Politécnica. Programa de Pós Graduação em Engenharia Industrial. Salvador, BA, BrasilOpioids have been used as the reference treatment on chronic pain. However, they are related to serious adverse effects which affect the patient compliance to treatment, as well as, his quality of life. Particulate formulations have been investigated as an alternative to improve opioid efficacy and safety

Sérgio Ferreira beyond Pharmacology: His Role as a Science Communicator

Historically, toxins from animal venoms have contributed significantly to the discovery of new drugs, as illustrated by captopril, the first drug developed from an animal toxin approved for human use [...

Antinociceptive properties of Micrurus lemniscatus venom

Submitted by Ana Maria Fiscina Sampaio ([email protected]) on 2013-11-14T18:05:41Z No. of bitstreams: 1 Gisele Graça Leite dos Santos Antinociceptive....pdf: 619941 bytes, checksum: b5a51fdefe0012c7691d360620260921 (MD5)Made available in DSpace on 2013-11-14T18:05:41Z (GMT). No. of bitstreams: 1 Gisele Graça Leite dos Santos Antinociceptive....pdf: 619941 bytes, checksum: b5a51fdefe0012c7691d360620260921 (MD5) Previous issue date: 2012Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, BrasilUniversidade Federal da Bahia. Instituto de Ciências da Saúde. Salvador, BA, Brasil / Universidade do Estado da Bahia. Departamento de Ciências da Vida. Salvador, BA, BrasilFundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil / Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, BrasilFundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Farmácia. Salvador, BA, BrasilThe therapeutic potential of snake venoms for pain control has been previously demonstrated. In the present study, the antinociceptive effects of Micrurus lemniscatus venom (MlV) were investigated in experimental models of pain. The antinociceptive activity of MIV was evaluated using the writhing, formalin, and tail flick tests. Mice motor performance was assessed in the rota rod and open field tests. In a screening test for new antinociceptive substances – the writhing test – oral administration of MlV (19.7–1600 mg/ kg) produced significant antinociceptive effect. The venom (1600 mg/kg) also inhibited both phases of the formalin test, confirming the antinociceptive activity. The administration of MlV (1600 mg/kg) did not cause motor impairment in the rota rod and open field tests, which excluded possible non-specific muscle relaxant or sedative effects of the venom. The MIV (177–1600 mg/kg) also increases the tail flick latency response, indicating a central antinociceptive effect for the venom. In this test, the MlV-induced antinociceptive effect was long-lasting and higher than that of morphine, an analgesic considered the gold standard. In another set of experiments, the mechanisms involved in the venom-induced antinociception were investigated through the use of pharmacological antagonists. The MlV (1600 mg/kg) antinociceptive effect was prevented by naloxone (5 mg/kg), a nonselective opioid receptor antagonist, suggesting that this effect is mediated by activation of opioid receptors. In addition, the pre-treatment with the m-opioid receptor antagonist CTOP (1 mg/kg) blocked the venom antinociceptive effect, while the k-opioid receptor antagonist nor-BNI (0.5 mg/kg) or the d-opioid receptor antagonist naltrindole (3 mg/kg) only partially reduced the venom-induced antinociception. The present study demonstrates, for the first time, that oral administration of M. lemniscatus venom, at doses that did not induce any motor performance alteration, produced potent and long-lasting antinociceptive effect mediated by activation of opioid receptors

The peripheral pro-nociceptive state induced by repetitive inflammatory stimuli involves continuous activation of protein kinase A and protein kinase C epsilon and its Na(v)1.8 sodium channel functional regulation in the primary sensory neuron

In the present study, the participation of the Na(v)1.8 sodium channel was investigated in the development of the peripheral pro-nociceptive state induced by daily intraplantar injections of PGE(2) in rats and its regulation in vivo by protein kinase A (PKA) and protein kinase C epsilon (PKC epsilon) as well. In the prostaglandin E(2) (PGE(2))-induced persistent hypernociception, the Na(v)1.8 mRNA in the dorsal root ganglia (DRG) was up-regulated. The local treatment with dipyrone abolished this persistent hypernociception but did not alter the Na(v)1.8 mRNA level in the DRG. Daily intrathecal administrations of antisense Na(v)1.8 decreased the Na(v)1.8 mRNA in the DRG and reduced ongoing persistent hypernociception. once the persistent hypernociception had been abolished by dipyrone, but not by Na(v)1.8 antisense treatment, a small dose of PGE(2) restored the hypernociceptive plateau. These data show that, after a period of recurring inflammatory stimuli, an intense and prolonged nociceptive response is elicited by a minimum inflammatory stimulus and that this pro-nociceptive state depends on Na(v)1.8 mRNA up-regulation in the DRG. in addition, during the persistent hypernociceptive state, the PKA and PKC epsilon expression and activity in the DRG are up-regulated and the administration of the PKA and PKC epsilon inhibitors reduce the hypernociception as well as the Na(v)1.8 mRNA level. In the present study, we demonstrated that the functional regulation of the Na(v)1.8 mRNA by PKA and PKC epsilon in the primary sensory neuron is important for the development of the peripheral pro-nociceptive state induced by repetitive inflammatory stimuli and for the maintenance of the behavioral persistent hypernociception. (C) 2008 Elsevier Inc. All rights reserved

Anti-inflammatory effects of carvacrol: evidence for a key role of interleukin-10.

Submitted by Ana Maria Fiscina Sampaio ([email protected]) on 2014-10-08T17:50:13Z No. of bitstreams: 1 Lima MS Anti-inflammatory effects....pdf: 662172 bytes, checksum: 5563e5b4c78778c04c1b7009fb92e829 (MD5)Approved for entry into archive by Ana Maria Fiscina Sampaio ([email protected]) on 2014-10-08T17:50:24Z (GMT) No. of bitstreams: 1 Lima MS Anti-inflammatory effects....pdf: 662172 bytes, checksum: 5563e5b4c78778c04c1b7009fb92e829 (MD5)Made available in DSpace on 2014-10-08T18:03:30Z (GMT). No. of bitstreams: 1 Lima MS Anti-inflammatory effects....pdf: 662172 bytes, checksum: 5563e5b4c78778c04c1b7009fb92e829 (MD5) Previous issue date: 2013Universidade Federal da Bahia. Faculdade de Farmácia. Salvador, BA, BrasilUniversidade Federal de Sergipe. Departamento de Fisiologia. São Cristóvão, SE, BrasilUniversidade Estadual de Feira de Santana. Feira de Santana, BA, BrasilHospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, BrasilHospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, BrasilUniversidade Federal da Bahia. Faculdade de Farmácia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, BrasilCarvacrol,aphenolicmonoterpene,hasbeenreportedtopossessanti-inflammatoryproperties. However,themechanismsinvolvedinitspharmacologicalpropertiesarecurrentlynotwellunder- stood. Inthepresentstudy,thecontributionofcytokinemodulationtotheanti-inflammatoryeffectsof carvacrolwasinvestigatedinaclassicalinflammationmodel:thecompleteFreund’sadjuvant(CFA)- inducedpawinflammationinmice.Thepawedemawasmeasuredusingaplesthismometer.Pawtissue was removed2haftertheinflammatorystimulustodeterminethelevelsofprostaglandinE2 (PGE2) by enzyme immunoassay,thelevelsofinterleukin-1 b (IL-1b), tumornecrosisfactor-a (TNF-a), and interleukin-10(IL-10)byELISAorthemRNAexpressionofcyclooxygenase-2(COX-2),IL-1b, TNF-a, and IL-10 byreal-timePCR.Administrationofcarvacrolproducedanti-inflammatoryeffectsagainstCFA- inducedinflammationinmice.Treatmentofmicewithcarvacrolat50and100mg/kgattenuatedthe paw edemaandreducedtheIL-1b and PGE2, butnotTNF-a, locallevels.Similarly,carvacrol(100mg/kg) reducedtheCOX-2andIL-1b mRNA expression.ThelevelsofIL-10,ananti-inflammatorycytokine,and the IL-10mRNAexpressionintheinflamedpawwereenhancedbycarvacrol.Inaddition,thetreatment with carvacroldidnotreducetheCFA-inducedpawedemainIL-10knockoutmice.Thepresentresults suggestthatcarvacrolcausesanti-inflammatoryeffectsbyreducingtheproductionofinflammatory mediators,suchasIL-1b and prostanoids,possiblythroughtheinductionofIL-10release

Antinociceptive properties of bergenin

Submitted by Ana Maria Fiscina Sampaio ([email protected]) on 2014-11-27T19:01:31Z No. of bitstreams: 1 Oliveira C M Antinociceptive....pdf: 1420717 bytes, checksum: 4247706d26a36f804881821f95401fc6 (MD5)Approved for entry into archive by Ana Maria Fiscina Sampaio ([email protected]) on 2014-11-27T19:01:39Z (GMT) No. of bitstreams: 1 Oliveira C M Antinociceptive....pdf: 1420717 bytes, checksum: 4247706d26a36f804881821f95401fc6 (MD5)Made available in DSpace on 2014-11-27T19:13:52Z (GMT). No. of bitstreams: 1 Oliveira C M Antinociceptive....pdf: 1420717 bytes, checksum: 4247706d26a36f804881821f95401fc6 (MD5) Previous issue date: 2011Universidade Federal da Bahia. Salvador, BA, BrasilFundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, BrasilUniversidade Estadual de Feira de Santana. Feira de Santana, BA, BrasilUniversidade Federal da Bahia. Salvador, BA, BrasilUniversidade Federal da Bahia. Salvador, BA, BrasilFundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, BrasilUniversidade Federal da Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, BrasilBergenin (1) is a C-glucoside of 4-O-methylgallic acid with known antiarthritic activity attributed to modulation of cytokine production. The present study was undertaken to evaluate whether 1 has antinociceptive properties in models of inflammatory pain and to investigate its possible mechanisms of action. Pretreatment with 1 (12.5-100 mg/kg, ip) produced a dose-related inhibition of acetic acid-induced writhing in mice. Furthermore, treatment with 1 (50 and 100 mg/kg) inhibited both the early and late phases in a formalin test. In addition, 1 (50 and 100 mg/kg, ip) inhibited mechanical hyperalgesia, edema, and paw production of hyperalgesic cytokines (TNF-α and IL-1ß) induced by complete Freund's adjuvant. However, the local production of IL-10, an anti-inflammatory cytokine, was not altered by 1 (100 mg/kg, ip). Treatment with 1 produced a similar profile of antinociception in wild-type and IL-10-deficient mice. Mice treated with 1 did not show any motor performance alterations or apparent systemic toxicity. The results presented herein demonstrate that bergenin has consistent antinociceptive and anti-inflammatory properties, acting by the inhibition of IL-1ß and TNF-α production, and suggest its potential for the control of inflammatory pain

Alpha-Lipoic Acid as an Antioxidant Strategy for Managing Neuropathic Pain

Neuropathic pain (NP) is the most prevalent and debilitating form of chronic pain, caused by injuries or diseases of the somatosensory system. Since current first-line treatments only provide poor symptomatic relief, the search for new therapeutic strategies for managing NP is an active field of investigation. Multiple mechanisms contribute to the genesis and maintenance of NP, including damage caused by oxidative stress. The naturally occurring antioxidant alpha-lipoic acid (ALA) is a promising therapeutic agent for the management of NP. Several pre-clinical in vitro and in vivo studies as well as clinical trials demonstrate the analgesic potential of ALA in the management of NP. The beneficial biological activities of ALA are reflected in the various patents for the development of ALA-based innovative products. This review demonstrates the therapeutic potential of ALA in the management of NP by discussing its analgesic effects by multiple antioxidant mechanisms as well as the use of patented ALA-based products and how technological approaches have been applied to enhance ALA’s pharmacological properties